Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension.
Reichen
J
J
Department of Clinical Pharmacology, University of Berne, Switzerland.
D001775:Blood Circulation; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D005355:Fibrosis / Q000503:physiopathology; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D008099:Liver / Q000503:physiopathology*; D008722:Methods; D008955:Models, Cardiovascular; D009566:Nitrates / Q000627:therapeutic use; D011168:Portal System / Q000503:physiopathology; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013564:Sympathetic Nervous System / Q000503:physiopathology; D013566:Sympathomimetics / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D009566:Nitrates; D011448:Prostaglandin Antagonists; D012702:Serotonin Antagonists; D013566:Sympathomimetics